Lv64
2960 积分 2023-09-25 加入
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]
22天前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]
1个月前
已完结
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer
2个月前
已完结
Cancer incidence and mortality in China, 2022
2个月前
已完结
抗肿瘤新药突破性治疗药物认定的标准及考虑
2个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
4个月前
已完结
Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study
5个月前
已完结
皖公网安备34019202002308
